Acylated glucagon analogue

1. A compound having the formula:

R 1 -H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-heptadecanoyl]-isoGlu-GSGSGG)-A-R 2   (SEQ ID NO: 1)

wherein

R 1 is H (hydrogen), C 1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; and

R 2 is OH or NH 2 ;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 which is:

H-H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-heptadecanoyl]-isoGlu-GSGSGG)-A-NH 2    (SEQ ID NO: 1)

or a pharmaceutically acceptable salt thereof.

3. A composition comprising a compound according to claim 1 in admixture with a carrier.

4. A composition according to claim 3 wherein the composition is a pharmaceutical composition, and the carrier is a pharmaceutically acceptable carrier.

5. A method of preventing weight gain or promoting weight loss in an individual in need thereof comprising administering an effective amount of a compound according to claim 1 .

6. A method of lowering circulating LDL levels, and/or increasing HDL/LDL ratio in an individual in need thereof comprising administering an effective amount of a compound according to claim 1 .

7. A method of improving glycemic control or of prevention or treatment of obesity, morbid obesity, morbid obesity prior to surgery, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, diabetes, metabolic syndrome, hypertension, atherogenic dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or microvascular disease comprising administering an effective amount of a compound according to claim 1 .

8. The method according to claim 5 , wherein the compound is administered as part of a combination therapy together with an agent for treatment of diabetes, obesity, dyslipidemia or hypertension.

9. The method according to claim 8 wherein the agent for treatment of diabetes is a biguanide, a sulfonylurea, a meglitinide or glinide, a DPP-IV inhibitor, an SGLT2 inhibitor, a glitazone, a GLP-1 receptor agonist, an SGLT2 inhibitor, a GPR40 agonist, or an insulin or an insulin analogue.

10. The method according to claim 8 , wherein the agent for treatment of obesity is a GLP-1 receptor agonist, peptide YY or analogue thereof, neuropeptide Y (NPY) or an analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, Human prolslet Peptide (HIP), melanocortin receptor 4 agonist, melanin concentrating hormone receptor 1 antagonist, phentermine (alone or in combination with topiramate), a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist, Orlistat™, Sibutramine™, CCK, amylin, pramlintide and leptin and analogues thereof, or a serotonergic agent.

11. The method according to claim 8 wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker.

12. The method according to claim 8 wherein the agent for treatment of dyslipidemia is a statin, a fibrate, a niacin, a PSCK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor and/or a cholesterol absorption inhibitor.

13. A therapeutic kit comprising a compound according to claim 1 .

14. A method of synthesis of a compound according to claim 1 , wherein the synthesis comprises the step of solid-phase or liquid-phase peptide coupling in a method for synthesizing said compound.

15. A method of producing a compound according to claim 1 , the method comprising expressing a precursor peptide sequence from a nucleic acid construct that encodes the precursor peptide, recovering the expression product, and modifying the precursor peptide to yield a compound according to claim 1 .